Orthofix Medical Inc. (OFIX) Debt Components
- 2026-06-30: Long-term Debt, Current MaturitiesUSD (m); Long-term Debt, Excluding Current MaturitiesUSD $221.59M; Long-term Line of CreditUSD (m); Long-term DebtUSD (m).
- 2026-03-31: Long-term Debt, Current MaturitiesUSD (m); Long-term Debt, Excluding Current MaturitiesUSD $221.34M; Long-term Line of CreditUSD (m); Long-term DebtUSD (m).
- 2025-12-31: Long-term Debt, Current MaturitiesUSD (m); Long-term Debt, Excluding Current MaturitiesUSD $157.39M; Long-term Line of CreditUSD (m); Long-term DebtUSD (m).
- 2025-12-31: Long-term Debt, Current MaturitiesUSD $0.00; Long-term Debt, Excluding Current MaturitiesUSD (m); Long-term Line of CreditUSD (m); Long-term DebtUSD (m).
Orthofix Medical Inc. Debt Components
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Long-term Debt, Current Maturities USD | Long-term Debt, Excluding Current Maturities USD | Long-term Line of Credit USD | Long-term Debt USD | Long-Term Debt, Maturity, Year One USD | Long-Term Debt, Maturity, Year Two USD | Long-Term Debt, Maturity, Year Three USD | Long-Term Debt, Maturity, Year Four USD | Line of Credit Facility, Maximum Borrowing Capacity EUR | Line of Credit Facility, Maximum Borrowing Capacity USD | Line of Credit Facility, Interest Rate at Period End pure | Debt Instrument, Fair Value Disclosure USD | Line of Credit Facility, Amount Outstanding (Deprecated 2014-01-31) USD |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $221.59M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | (m) | $221.34M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | $157.39M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | (m) | $157.22M | (m) | $157.22M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | $157.05M | (m) | $157.05M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | $156.88M | (m) | $156.88M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $0.00 | $157.01M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | (m) | (m) | $157.01M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-11-07 | (m) | (m) | $125.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $6.25M | $112.22M | (m) | $118.47M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $4.69M | $113.31M | (m) | $118.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $3.12M | $115.07M | (m) | $118.20M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $1.25M | $93.11M | (m) | $94.36M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | (m) | $70.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | $51.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | $45.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | $100.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 5.80M | $7.00M | (m) | $16.10M | (m) |
| 2017-09-30 | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) | (m) | 5.80M | $6.90M | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) | (m) | 5.80M | $6.60M | (m) | (m) | (m) |
| 2017-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $9.00M | (m) |
| 2017-03-31 | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) | (m) | 5.80M | $6.20M | (m) | (m) | (m) |
| 2016-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $6.10M | (m) | (m) | (m) |
| 2016-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 5.80M | (m) | (m) | $12.20M | (m) |
| 2016-09-30 | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) | (m) | 5.80M | $6.50M | (m) | (m) | (m) |
| 2016-06-30 | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) | (m) | 5.80M | $6.40M | (m) | (m) | (m) |
| 2016-03-31 | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) | (m) | 5.80M | $6.60M | (m) | (m) | (m) |
| 2015-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $6.30M | (m) | (m) | (m) |
| 2015-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 5.80M | (m) | (m) | (m) | (m) |
| 2015-09-30 | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) | (m) | 5.80M | $6.50M | (m) | (m) | (m) |
| 2015-06-30 | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | $6.50M | (m) | (m) | (m) |
| 2015-03-31 | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | $6.20M | (m) | (m) | (m) |
| 2014-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $7.00M | (m) | (m) | (m) |
| 2014-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 5.80M | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | (m) | $0.00 | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-09-30 | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) | (m) | 5.80M | $7.30M | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 5.80M | $8.00M | (m) | (m) | $0.00 |
| 2014-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 5.80M | $8.00M | (m) | (m) | $0.00 |
| 2014-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 3.70% | (m) | (m) |
| 2013-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 5.80M | $8.00M | (m) | (m) | (m) |
| 2013-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 3.70% | (m) | $0.00 |
| 2013-12-31 | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 5.80M | $7.80M | (m) | (m) | $0.00 |
| 2013-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 5.80M | $7.50M | (m) | (m) | $0.00 |
| 2013-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 5.80M | $7.40M | (m) | (m) | $0.00 |
| 2012-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 5.80M | $7.60M | 3.70% | (m) | $100.00K |
| 2012-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 4.96% | (m) | $300.00K |
| 2012-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 3.41% | (m) | $500.00K |
| 2012-03-31 | $20.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 6.47% | (m) | $1.40M |
| 2011-12-31 | $17.50M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 6.30M | $8.10M | 4.00% | (m) | $1.30M |
| 2011-12-31 | (m) | (m) | (m) | (m) | $17.50M | $25.00M | $26.30M | $139.90M | (m) | (m) | (m) | (m) | (m) |
| 2011-09-30 | $15.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | $12.50M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $7.50M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 3.57% | (m) | $3.80M |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Orchestra BioMed Holdings, Inc. (OBIO) | United States | $0.356B | -4.39 |
| SHOULDER INNOVATIONS, INC. (SI) | United States | $0.355B | |
| CARLSMED, INC. (CARL) | United States | $0.405B | |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| ClearPoint Neuro, Inc. (CLPT) | United States | $0.446B | -15.74 |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |